News
Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...
Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results